Tetra Bio Pharma Inc (TBPMQ)

[greenwillow]

Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain

ORLEANS, Ontario, June 18, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada. PPP001 will investigate cannabis as an alternative to fentanyl in the management of breakthrough pain. Santé Cannabis is a Quebec-based medical clinic specialized in clinical research and cannabis - based therapies.

https://www.ftmig.com/cannabis-marijuana/tetra-bio-pharma-takes-on-fentanyl-in-head-to-head-trial-for-the-treatment-of-breakthrough-pain/